Advanced Tumors Clinical Trial
Official title:
A Phase I, Multicenter, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-A83 in Patients With Advanced Malignant Neoplasm
This is an open-label, first-in-human (FIH) Phase I study to evaluate the safety, tolerability, and preliminary efficacy of a humanized anti-CD47 monoclonal antibody (HMPL-A83) in patients with advanced malignant neoplasm.
This is an open-label, first-in-human (FIH) Phase I study to evaluate the safety, tolerability, and preliminary efficacy of a humanized anti-CD47 monoclonal antibody (HMPL-A83) in patients with advanced malignant neoplasm. The sample size of this study is mainly based on the design of classical 3 + 3 combined accelerated titration dose escalation with a total of 6 dose groups, and approximately 31-84 patients are expected to be enrolled. During the dose escalation, DLT-nonevaluable patients will be replaced, or the actual number of patients enrolled may exceed the planned one due to adjustment of escalation schedule during the dose escalation. It is expected that no more than 99 patients will be enrolled. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06245122 -
A Study of CS23546 in Subjects With Advanced Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06314087 -
iTAPVR Study - Phase II Randomized Study
|
Phase 2 | |
| Recruiting |
NCT05390528 -
A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02419417 -
Study of BMS-986158 in Subjects With Select Advanced Cancers
|
Phase 1/Phase 2 | |
| Completed |
NCT04808453 -
Phase I Study of CPI-300 in Patients With Advanced Tumors
|
Phase 1 | |
| Recruiting |
NCT05799183 -
A SHR-1210 BE Study on Healthy Subjects
|
Phase 1 | |
| Terminated |
NCT04198818 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05213767 -
Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT04151810 -
Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05068856 -
A Study of HRS2543 in Patients With Advanced Tumors
|
Phase 1 | |
| Completed |
NCT03781362 -
Study of CPI-100 in Patients With Advanced Tumors
|
Phase 1 | |
| Recruiting |
NCT03908814 -
Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05061628 -
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor
|
Phase 1 | |
| Recruiting |
NCT05867771 -
A Study of PM1022 in Patients With Advanced Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03444714 -
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
|
Phase 1 |